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SUMMARY
Because the accumulation and activation of mononuclear phagocytes are critical to the
host response to intracellular microbial pathogens, we evaluated mechanisms of
peripheral monocyte leucotactic regulation in leprosy. Plasma from 53 of 67 patients was
found to inhibit the locomotion of normal human monocytes. Neither the prevalence nor
the magnitude of plasma leucotactic inhibitory activity correlated with disease histology
or duration, type or duration of chemotherapy, or history of erythema nodosum
leprosum. Plasma leucotactic inhibitory activity resided principally in a non-immunoglo-
bulin, cell-directed inhibitor of 230,000 daltons molecular weight. Fractionation of
plasma from patients with lepromatous leprosy revealed an additional, immunoglobulin-
containing inhibitor of approximately 400,000 daltons weight, possibly an IgG-IgA
immune complex. Production of leucotactic inhibitors by unstimulated and concanavalin
A-stimulated peripheral mononuclear cells was normal; however, cutaneous explants
from these patients spontaneously produced the 230,000 dalton leucotactic inhibitor in
vitro. The ability of the lesions of leprosy to impede monocyte traffic may be an important
pathogenetic mechanism.
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INTRODUCTION
Active infection with Mycobacterium leprae is characterized by a broad spectrum of host responses,
marked by great variability in histopathology, cellular immune reactivity, and clinical course of
infection. The pathophysiological basis for this variability is not yet clear though genetic influences
seem likely. Nevertheless, as M. leprae resides primarily in mononuclear phagocytes, the ability of
these cells to cope with the leprosy bacillus is an issue central to the understanding of host resistance
to infection.
Many leprosy patients manifest defects of phagocyte locomotion, due at least in part to
leucotactic inhibitors in plasma and serum (Masuda & Scheinberg, 1980; Azulay, 1982; Ward,
Goralnik & Bullock, 1976). We have found that peripheral monocytes from patients infected with
Mycobacterium tuberculosis also display defective leucotactic responsiveness, due to the increased
activity in plasma of a specific, cell-directed inhibitor of monocyte leucotaxis (Campbell, 1979). In
our subsequent studies, we have found that such inhibitory activity reflects the pathological
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activation by mycobacterial products of a subpopulation of peripheral blood mononuclear cells
with natural killer-like characteristics. Since a microbial mechanism for subverting the mobilization
and activation of mononuclear phagocytes could be a powerful determinant of the outcome of host-
parasite interactions in other mycobacterioses, we have initiated studies of the regulation of
monocyte and macrophage traffic in leprosy patients.
MATERIALS AND METHODS
Subjects. The study subjects were drawn from the inpatient and outpatient populations of the
Gillis Long Hansen's Disease Center and participated after granting signed, informed consent.
Disease staging was based upon clinical criteria as well as classification of skin biopsies according to
the scheme of Ridley & Jopling (1966). The study population included patients in the tuberculoid
(TT) and polar lepromatous (LL) stages of disease as well as patients with borderline tuberculoid
(BT) and borderline lepromatous (BL) leprosy. No patient had manifestations of erythema
nodosum leprosum or a reversal reaction at the time of study. The normal control subjects were
employees of the Hansen's Disease Center and the East Carolina University School of Medicine
who were free of known disease and who were taking no medication.
Generation of leucotactic inhibitors. Heparinized peripheral venous blood was separated on
Ficoll-Hypaque gradients (Bdyum, 1968). After two washings, the mononuclear cells were
suspended in RPMI 1640 (Grand Island Biological Co., Grand Island, NY) containing 10% heat-
inactivated newborn calf serum, 50 U of penicillin and 50 Mg of streptomycin per ml, and 2 mM
L-glutamine with or without 100 Mg/ml ofconcanavalin A (Pharmacia Fine Chemicals, Piscataway,
NJ). After 5 h, the cells were centrifuged and resuspended in stimulant-free medium to complete a 72
h incubation at 370C in humidified 5% CO2 before harvest and freezing of the supernatant.
Punch biopsies (2 mm) of clinically apparent cutaneous lesions were taken and cultured in 3 ml
volumes of medium. The entire supernatant was harvested daily and the culture volume restored
with fresh medium. Whenever possible, biopsies for culture were taken from sites adjacent to those
used to stage the disease.
Assay of leucotactic inhibitory activity. Samples of normal human mononuclear cells were
incubated for 30 min in either TC Medium 199 containing 2% bovine serum albumin (BSA, United
States Biochemical Corp., Cleveland, OH) or in undiluted culture supernatant or heparinized (10 U
per ml ofblood) plasma (Campbell, Thomas & Tolson, 1982). Each sample was then resuspended at
x 106 monocytes per ml of TC 199/2% BSA and leucotactic responsiveness to 10% zymosan-
activated normal human serum determined in blind-well leucotaxis chambers divided by a sandwich
ofa 5 gm pore size polycarbonate (Nucleopore, A.H. Thomas Co., Philadelphia, PA) and a 0-45Hm
pore size cellulose nitrate (Sartorius Membranfilter, Science Essentials Co., Anaheim, CA). The
responses of the supernatant (or plasma)-preincubated (MLxspN) and BSA-preincubated (MLXBSA)
cells were compared and inhibitory activity calculated by:
% inhibition=(I -MLXSPN/MLXBSA)x 100.
In some experiments, leucotactic responsiveness was also assessed to 10-7 M formyl-
methionylleucylphenylalanine (Sigma) and to the 72 h supernatants of normal peripheral blood
lymphocytes (1 x 106/ml of RPMI 1640 with supplements) stimulated with 10 mg/ml of concanava-
lin A.
Chromatographic techniques. Samples of plasma and culture supernatants were applied to
0-9 x 15 cm columns of a goat anti-total human immunoglobulins preparation (G, A, and M,
Cappel Laboratories, Cochranville, PA) coupled to Sepharose 4B (Pharmacia) at 5 mg of antibody
per ml of gel. These columns had a specific capacity of approximately 20 mg of IgG. The columns
were washed with 01 M NaHCO3/0 5M NaCl (excluded fraction) and the retained material eluted
with 0-1M glycine hydrochloride/0O5 M NaCl, pH 2 5 and the eluate pH adjusted to 7-0 with I M
NaOH (eluted fractions). The fractions were dialysed against 001 M phosphate-buffered saline
(PBS), pH 7 0, before further use.
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Fig. 1. Plasma leucotactic inhibitory activity in patients with polar tuberculoid (TT), borderline tuberculoid
(BT), borderline lepromatous (BL), and polar lepromatous (LL) leprosy. The vertical bars represent the group
means+ 1 s.d. and the shaded area the normal mean+ 2 s.d.
The immunoaffinity chromatography fractions were concentrated 10-fold by pressure ultra-
filtration in Amicon chambers fitted with YM10 Diaflo membranes (Amicon Corp., Lexington,
MA) before application to 15 x 80 cm columns of Bio-Gel A-1i5 m (Bio-Rad Laboratories,
Richmond, CA) calibrated with urease (Miles Laboratories, Elkhart, IN), catalase (Pharmacia),
immunoglobulin G (Sigma Chemical Corp., St Louis, MO), and bovine serum albumin (Sigma).
The columns were eluted with PBS.
Statistics. The results were evaluated by Chi square analysis and by rank sum (Mann-Whitney)
and rank order testing (Colton, 1974).
RESULTS
Plasma leucotactic inhibitory activity. Plasma from 79% of the 67 patients contained
supernormal leucotactic inhibitory activity. While preincubation of normal monocytes in 15
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Fig. 2. A representative chromatogram ofplasma from a patient with tuberculoid leprosy. The plasma was first
depleted of immunoglobulin by immunoaffinity chromatography and then applied to a column of Bio-Gel A-
1 5m calibrated with urease (U, 483,000 daltons), catalase (C, 235,000 daltons), IgG (I, 150,000 daltons), and
bovine serum albumin (B, 67,000 daltons). Inhibitory activity is indicated by the shaded area and eluate
absorbance at 280 nm by the dotted line. Inhibitory activity in the unfractionated plasma was 37 0%.
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Fig. 3. A representative fractionation of plasma from a patient with lepromatous leprosy. Inhibitory activity in
the unfractionated plasma was 33 9%. (Left) Data from the non-immunoglobulin fraction; (right) the
immunoglobulin fraction initially retained by the anti-immunoglobulin column. Inhibitory activity is indicated
by the shaded areas and eluate absorbance at 280 nm by the broken lines. The shaded bar at the left ofeach panel
represents the activity in that fraction before application to the Bio-Gel column.
samples of normal plasma inhibited leucotactic responsiveness to zymosan-activated normal
human serum by 5 6+4 5% (mean+ I s.d.), significant inhibitory activity (> 15%), ranging from
17 0 to 45-5%, was detected in the plasma of 53 patients.
The prevalence and magnitude of plasma leucotactic inhibitory activity were unrelated to the
position of the patient in the leprosy spectrum. As shown in Fig. 1, there were no significant
differences among the two TT, 15 BT, 13 BL, and 37 LL patients. Similarly, neither the prevalence
nor magnitude of inhibitory activity was related to disease duration, treatment status, inclusion of
prednisone in disease therapy, or, in the lepromatous patients, a history of antecedent erythema
nodosum leprosum.
Characterization of the plasma leucotactic inhibitors. Samples of plasma from three (two for
polar tuberculoid) patients representative of each histological classification were sequentially
Table 1. Monocyte leucotactic inhibitory activity in the 72 h culture supernatants of peripheral blood
mononuclear cells
Supernatant activity*
Concanavalin A
Donors (N) Unstimulated (100 pg/ml)
Normal(15) 54+76 386+102
Leprosy(27) 2 7+6l1t 34 2+ 8l1t
TT(1) 0-0 305
BT (6) 00+O± t 30 3+ 8-4t
BL (4) 3 5+7Ot 36 6+ 9 2t
LL(16) 21+43t 353+ 8-Ot
* Expressed as the percentage inhibition of
leucotactic responsiveness of normal monocytes
preincubated in the indicated supernatant com-
pared to the responsiveness of monocytes preincu-
bated in 2% bovine serum albumin.
t P> 0 05 compared to normal values.
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Fig. 4. Explant culture supernatant leucotactic inhibitory activity in normal controls (NL) and in patients with
leprosy. The vertical bars represent the group means. The explants were cultured in 3 ml volumes of tissue
culture medium and the supernatants harvested daily.
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Fig. 5. Representative Bio-Gel A- 1 5m fractionations of culture supernatants of cutaneous biopsies from one
patient each with (left) polar tuberculoid disease, and (right) polar lepromatous disease. Inhibitory activity is
indicated by the shaded areas and eluate absorbance at 280 nm by the broken lines. The shaded bar at the left of
each panel represents the activity in that fraction before application to the Bio-Gel column.
fractionated by anti-immunoglobulin immunoaffinity and gel chromatography. Plasma from the
polar and borderline tuberculoid and the borderline lepromatous patients yielded a single, non-
immunoglobulin species of inhibitor which eluted from the Bio-Gel A- -5m columns with an
approximate molecular weight of 230,000 daltons. This inhibitor is similar to the cell-directed
inhibitor of monocyte leucotaxis, CDI-Mlx, which is devoid of intrinsic leucotactic activity and
which acts to inhibit locomotor responses to a variety of soluble mediators, including C5a,
leucotactic lymphokines, and formyl-methionylleucylphenylalanine (FMLP, Campbell & Tolson,
1986). To address this relationship more directly, pools of the gel chromatography fractions
containing this inhibitor were also tested for their leucotactic activity. In three experiments, no
significant monocyte leucotactic activity was detected (2-5 + 0-7 monocytes per field vs 2-3 + 0-3 with
TC 199 vs 21-5 + 1-7 with zymosan-activated serum). No inhibitory activity was detectable in the
fractions eluted from the immunoaffinity columns with these samples.
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Plasma from lepromatous leprosy patients contained the non-immunoglobulin leucotactic
inhibitor as well as a second inhibitor, which was retained by the anti-immunoglobulin columns and
had an approximate molecular weight of 400,000 daltons. This immunoglobulin inhibitor was
present both in lepromatous patients with and without a history of antecedent erythema nodosum
leprosum. On double immunodiffusion, this 400,000 dalton fraction gave a line of partial identity
with IgA and IgG with an IgG spur. No IgM or C5 was detected in that fraction. Representative
chromatographs are presented in Figs 2 and 3. In contrast with the non-immunoglobulin inhibitor,
this 400,000 dalton inhibitor was intrinsically leucotactic, displaying activity equivalent to that of
zymosan-activated normal human serum. Preincubation of normal monocytes in the 400,000
dalton fraction deactivated the cells for migration toward zymosan-activated serum but did not
impair responses to leucotactic lymphokines present in the supernatants of concanavalin A-
stimulated normal lymphocytes or FMLP.
Generation of leucotactic inhibitors by peripheral blood mononuclear cells. We next sought to
ascertain whether the increased plasma leucotactic inhibitory activity detected in these patients
reflected spontaneous production by peripheral mononuclear cells, as is the case in patients infected
with Mycobacterium tuberculosis. The 72 h supernatants of unstimulated and concanavalin A-
stimulated peripheral mononuclear cells from 27 patients were assayed for inhibitory activity. As
shown in Table 1, there was no evidence for spontaneous production of leucotactic inhibitory
activity by peripheral blood mononuclear cells of leprosy patients. Moreover, the inhibitory activity
in mitogen-stimulated cultures from these patients did not differ from that in cultures from 15
normal subjects. No significant differences emerged when these data were analysed by disease
classification.
Spontaneous inhibitor production by explanted cutaneous lesions. Since a peripheral origin for the
increased plasma leucotactic inhibitory could not be identified, we next evaluated whether such
activity might reflect inhibitor production within the foci of infection. Punch biopsies of cutaneous
lesions from 19 patients were taken and culture supernatants harvested daily for three days. As
shown in Fig. 4, the culture supernatants of cutaneous explants from six normal controls contained
no inhibitory activity. By contrast, the 24 h supernatants from 18 of the patient biopsies inhibited
the leucotactic responsiveness of normal monocytes by a mean of 29-9+448%. Leucotactic
inhibitory activity in the supernatants obtained on the second and third days ofculture were similar
(30.9+4 3 and 30 9+ 3-4% inhibition, respectively). The mean leucotactic inhibitory culture in
plasma from these 18 patients was 32-8 + 2-8%. No significant differences were detected when the
inhibitory activities in the supernatants from the first, second, or third days of culture were
compared among the one TT, three BT, three BL, and eleven LL biopsies. No inhibitory activity
was detected in any supernatant from the nineteenth patient, a 75-year-old male with borderline
lepromatous disease of 10 years' duration whose plasma inhibited normal monocyte leucotaxis by
36-1%.
Characterization ofthe explant supernatant leucotactic inhibitors. Pools were made of the culture
supernatants of explanted cutaneous lesions from patients representative of each histological
disease type of leprosy and then fractionated by immunoaffinity and gel chromatography as before.
In contrast with the plasma fractionations, which disclosed either one or, in polar lepromatous
disease, two leucotactic inhibitors, each of the culture supernatants contained only a single species
of inhibitor. As shown in the typical fractionations presented in Fig. 5, a non-immunoglobulin
inhibitor with a molecular weight of 230,000 daltons accounted for all of the activities in
supernatants from polar tuberculoid and polar lepromatous biopsies. Supernatants from
borderline patients yielded similar patterns.
DISCUSSION
The data presented here detail an abnormality of inflammatory regulation in patients infected with
Mycobacterium leprae. Plasma from the majority of such patients was found to contain patho-
logical concentrations of a non-immunoglobulin leucotactic inhibitor of 230,000 daltons molecular
weight. This leucotactic regulator is probably identical to CDI-MLx, the monocyte-specific,
cell-directed inhibitor we have detected in plasma from patients with active tuberculosis (Campbell,
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1979). Although the frequency and magnitude of plasma inhibitory activity did not correlate with
disease staging, fractionation of plasma from patients with polar lepromatous disease revealed the
presence of an additional, immunoglobulin-containing inhibitor of approximately 400,000 daltons
molecular weight. Peripheral mononuclear cell production of leucotactic regulators was normal;
however, cutaneous explants spontaneously elaborated the 230,000 dalton inhibitor during culture
in vitro, suggesting that the increased plasma CDI-MLx activity reflects production of this
substance within foci of disease.
These data complement previous observations of defective phagocyte locomotion in leprosy
patients. Ward and co-workers detected abnormalities of leucotactic factor inactivators in patients
with lepromatous disease (Ward et al., 1976). Subsequently, Masuda & Scheinberg (1980) reported
impaired monocyte leucotactic responses to lymphokines in both polar tuberculoid and leproma-
tous patients. Cell-directed leucotactic inhibitory activity was detected in plasma from those
patients, but was not characterized further. Defects of neutrophil locomotion, particularly marked
in patients with lepromatous disease and in those manifesting erythema nodosum leprosum, have
also been recognized and appear also to be related to circulating cell-directed inhibitors (Wahba,
Cohen & Sheskin, 1980). However, it is possible that these neutrophil defects may be an
epiphenomenon ofhyperimmunoglobulinaemia in these patients since immunoglobulinG has been
shown to inhibit neutrophil locomotion in vitro (Woronick, Malnick & Maderazo, 1981).
Our previous studies have indicated that the production of CDI-MLx by peripheral blood
mononuclear cells is an attribute exclusive to a non-cytotoxic subpopulation of natural killer-like
cells bearing the OKM 1 and Leu 7 but not the Leu 11 membrane antigens (Campbell & Tolson,
1986). Indeed, such cells appear capable of secreting a variety of immunoregulatory cytokines,
including interleukins I and 2, a- and y-interferons, and B cell growth factor (Scala et al., 1984;
Kasahara et al., 1983; Djeu et al., 1982; Pistoia et al., 1985). They may present antigen to T cells and
can act to suppress T and B cell functions in vitro (Scala et al., 1985; Tilden, Abo & Balch, 1983; Arai
et al., 1983). Thus, dysfunction of these immunoregulatory cells could have great relevance to the
pathogenesis of leprosy. Little is known, however, of natural killer cell numbers and function in
leprosy although Humphres, Gelber & Kraherbuhl (1982) noted abnormally low cytolytic activity
of these cells in peripheral blood from patients with concurrent erythema nodosum leprosum.
The leucotactic inhibitor detected in these patients probably has immunoregulatory actions
beyond the modulation of monocyte locomotion. We have recently found that CDI-MLx induces
monocyte prostanoid production in vitro and that this effect, as well as its effect on leucotaxis, can be
blocked with inhibitors of cyclooxygenase and thromboxane synthetase. Further, preincubation in
these agents in vitro or in the thromboxane A2 receptor antagonist, SQ 29,548, restores the
leucotactic responsiveness of tuberculous monocytes. Prostaglandin E2 and thromboxane A2 have
been shown to modulate the phagocytic and secretory function ofmononuclear phagocytes as well
as Ia antigen display, actions which might critically influence the outcome of host-mycobacterial
interactions in vivo (Razin, Bauminger & Globerson, 1978; Cahill & Hopper, 1982; Snyder, Beller&
Unanue, 1982).
The nature and origins of the immunoglobulin-containing inhibitor detected in lepromatous
plasma are not yet clear. While the concentration of circulating immune complexes is increased in
many patients with leprosy, the composition of the complexes varies with the disease classification
(Ramanatha et al., 1984). It may be relevant to the observations detailed here that complexes from
lepromatous patients are particularly likely to contain C-reactive protein, an acute-phase reactant
which exerts diverse effects on immune functions, including those of natural killer cells and
monocytes (Baum et al., 1983; Mortensen & Duszkiewicz, 1977).
The pathophysiological significance of the observations detailed here is uncertain. Our studies
have shown that CDi-MLx is one element in an immunoregulatory loop which includes natural
killer-like cells and monocytes and which causes the activation of monocyte arachidonic acid
metabolism. This loop might be supposed to act physiologically to focus mononuclear phagocytes
within inflammatory foci and to modulate the function of these immobilized cells. Our studies in
progress further suggest that the detection of increased CDI-MLx activity in plasma is a
pathological event. On the one hand, peripheral monocyte leucotactic responsiveness and plasma
CDI-MLx activity are normal in patients with deep mycoses due to Histoplasma capsulatum and
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Blastomyces dermatitidis. In tuberculosis, however, defective locomotor responsiveness and
increased inhibitor activity reflect the activation of this cellular cascade by circulating mycobacter-
ial products. The data presented here imply that increased plasma CDI-MLx in leprosy patients
reflects spillage from cutaneous foci. Whether such spillage impedes monocyte immigration into
inflammatory foci is speculative. If, however, CDI-MLx modulates monocyte maturation, these
observations may have great relevance to the ability of mononuclear phagocytes to deal with these
intracellular pathogens.
Inasmuch as the prevalence and magnitude of plasma inhibitory activity did not correlate with
histopathology, these data do not yet allow the conclusion that the detection ofincreased CDI-MLx
in leprosy has the same connotation as in other mycobacterial infections. These data do, however,
provide some preliminary insight into the potential of the lesions of leprosy to modulate systemic
immune responses. Immunoglobulin production, including the production of specific anti-
mycobacterial antibodies, by explanted lesions has previously been demonstrated (Lai A Fat et al.,
1979, 1980). The present study extends that perspective to include the elaboration of inflammatory
regulators by these lesions and suggests the possibility of a similar origin for soluble inhibitors of
other immune responses in these patients (Nelson et al., 1975).
These studies were supported in part by a grant from the National Institute of Allergy and Infectious Diseases,
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